# Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

* Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high
* Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure
* Nutriband’s Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch

 Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal technologies to deliver medications that require careful balancing of patient access with strong mitigation against misuse.

 Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high. Fentanyl is approximately 50 times more potent than heroin, and even trace amounts can be fatal, making it a dangerous ingredient when diverted or misused…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/nutriband-inc-nasdaq-ntrb-navigates-drug-delivery-challenges-with-innovation-in-abuse-deterrent-tech/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nutriband-innovates-with-abuse-deterrent-fentanyl-patch/1f686bc433a081d09e794804a6c68973) 

 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/258/6/leanW3V8.webp)